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Abstract
Background: Loss of functional UBE3A, an E3 protein ubiquitin ligase, causes 
Angelman syndrome (AS), a neurodevelopmental disorder characterized by severe 
developmental delay, speech impairment, epilepsy, movement or balance disorder, 
and a characteristic behavioral pattern. We identified a novel UBE3A sequence vari-
ant in a large family with eight affected individuals, who did not meet the clinical 
AS criteria.
Methods: Detailed clinical examination and genetic analysis was performed to es-
tablish the phenotypic diversity and the genetic cause. The function of the mutant 
UBE3A protein was assessed with respect to its subcellular localization, stability, 
and E3 ubiquitin ligase activity.
Results: All eight affected individuals showed the presence of a novel maternally 
inherited UBE3A sequence variant (NM_130838.4(UBE3A):c.1018-1020del, 
p.(Asn340del), which is in line with a genetic AS diagnosis. Although they presented 
with moderate to severe intellectual disability, the phenotype did not match the clini-
cal criteria for AS. In line with this, functional analysis of the UBE3A p.Asn340del 
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1 |  BACKGROUND
Angelman syndrome (AS: OMIM #105830), first described in 
1965 by Harry Angelman (Angelman, 1965), is a rare neurode-
velopmental disorder with a prevalence of 1:20.000 (Bird, 2014; 
Larson, Shinnick, Shaaya, Thiele, & Thibert, 2015; Mertz et al., 
2013; Prasad, Grocott, Parkin, Larson, & Thibert, 2018; Smith, 
2001). It is caused by deficient expression or function of the 
maternally inherited UBE3A gene. The most common cause 
of AS is a maternal 15q11-q13 deletion. Other known genetic 
causes are paternal uniparental disomy, genomic imprinting de-
fects, and intragenic variants in UBE3A (Buiting, Williams, & 
Horsthemke, 2016). Although these latter two groups tend to 
present with a milder phenotype, all these patients present with 
a well-defined AS phenotype, which is a profound to severe 
developmental delay, severe speech impairment, movement, or 
balance disorder such as ataxia of gait and/or tremulousness of 
the limbs, and a characteristic behavioral pattern. Other com-
mon features include epilepsy, microcephaly, and other charac-
teristic facial features, sleep disturbance, scoliosis, strabismus, 
and constipation (Williams et al., 2006). The natural course of 
AS in adulthood has been less well described (Larson et al., 
2015; Prasad et al., 2018; Smith, 2001).
The UBE3A gene (UBE3A; MIM #601623) encodes a 
HECT (homologous to the E6-AP carboxyl terminus) –type 
of E3 ubiquitin protein ligase. The C-terminal HECT do-
main harbors the catalytic cysteine residue that is essential 
for transferring the ubiquitin to either itself (auto-ubiquitina-
tion) or to substrate proteins, generally targeting the modified 
proteins for proteasomal degradation (de Bie & Ciechanover, 
2011; Huibregtse, Scheffner, Beaudenon, & Howley, 1995). 
In human, three UBE3A protein isoforms are described that 
harbor different N-termini: the two long isoforms, isoforms 2 
and 3, each have an N-terminal extension of, respectively, 23 
and 20 amino acids compared to the short isoform (isoform 1) 
(Yamamoto, Huibregtse, & Howley, 1997). Mice express two 
protein isoforms, isoforms 2 and 3, which are highly homolo-
gous to the human isoforms 3 and 1, respectively (Avagliano 
Trezza et al., 2019; Greer et al., 2010). In human and mouse 
neurons UBE3A is mainly localized to the nucleus with 
smaller amounts present in axons and dendrites (Avagliano 
Trezza et al., 2019; Burette et al., 2016, 2018; Dindot, Antalffy, 
Bhattacharjee, & Beaudet, 2008). Recent work in mice has re-
vealed how this subcellular distribution of UBE3A is achieved: 
the short isoform (mUBE3A Iso3), which constitutes ~80% of 
total UBE3A, is mainly nuclear while the, less abundant, long 
isoform (mUBE3AIso2) is predominantly present in the cytosol 
(Avagliano Trezza et al., 2019; Miao et al., 2013). Analysis of 
isoform-specific mice suggests that in vivo the nuclear isoform 
of UBE3A, but not the cytosolic isoform, has a critical role in 
normal neurodevelopment (Avagliano Trezza et al., 2019).
AS is often caused by a microdeletion of the UBE3A gene, 
but ~10% of the patients are reported to have pathogenic mis-
sense variants that change one or a few amino acids in the 
UBE3A protein (Avagliano Trezza et al., 2019; Baumer, 
Balmer, & Schinzel, 1999; Camprubí et al., 2009; Cooper, 
Hudson, Amos, Wagstaff, & Howley, 2004; Fang et al., 1999; 
Sadikovic et al., 2014; Yi et al., 2015). Understanding if, and 
how, these missense mutations contribute to the pathogenesis 
of AS remains a challenge. Specifically, it requires genetic and 
clinical information of the patient carrying the UBE3A variant 
as well as detailed functional analysis of the mutant protein. 
For most AS-linked missense mutations reported in the litera-
ture functional characterization of the mutant protein is lacking. 
Here we report the clinical phenotype and functional character-
ization of a novel maternally inherited UBE3A sequence variant 
(NM_130838.4(UBE3A):c.1018-1020del, p.(Asn340del) that 
was identified in a large family during a Dutch study on the nat-
ural course of AS in adulthood. The eight related individuals af-
fected by this sequence variant do not, or only in a very limited 
manner, resemble AS and we provide a molecular explanation 
for the unusual mild phenotype of these patients.
2 |  METHODS
2.1 | Ethical compliance
The study was approved by the Medical Ethical Review Board 
of the Erasmus Medical Center, Rotterdam (MEC-2015-267). 
mutant protein revealed no major deficits in UBE3A protein localization, stability, or 
E3 ubiquitin ligase activity.
Conclusion: The p.(Asn340del) mutant protein behaves distinctly different from pre-
viously described AS-linked missense mutations in UBE3A, and causes a phenotype 
that is markedly different from AS. This study further extends the range of pheno-
types that are associated with UBE3A loss, duplication, or mutation.
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F I G U R E  1  Pedigree of the family carrying hUBE3A-p.Asn340del variant. (a) Family tree including results of haplotyping and DNA studies. 
(b) Images of all living patients harboring the UBE3A p.Asn340del variant
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Written informed consent was obtained from all individuals 
participating in the study.
2.2 | Recruitment of patients
From 2015 to 2016 adult individuals with genetically con-
firmed AS were included in a Dutch study to investigate the 
natural course of AS in adulthood. Parents or legal represent-
atives were recruited for the study via the Dutch Angelman 
parents association (Vereniging Angelman Syndroom 
Nederland) and the Dutch Society of Physicians for persons 
with intellectual disabilities. Furthermore, adults visiting the 
outpatient clinic of the Dutch expertise Center ENCORE 
(Dutch Expertise Center which gathers expertise of rare con-
genital neuro-cognitive developmental disorders, such as 
AS) were approached to participate.
Parents or legal representatives who were interested in 
participating were sent information regarding the study to 
decide upon participation in the study. Written informed con-
sent was thereafter obtained.
Individuals IV.3 and IV.4 (see Figure 1) were participants 
in the Dutch natural course study. Their mother informed us 
of other probands and approached her family members to par-
ticipate. All alive probands in this family were visited and 
blood samples were collected to clarify the genetic origin of 
their cognitive impairment.
2.3 | Medical history and clinical 
examination
All participants were visited by the researchers (IdB, 
AGH and MJV). Medical history was obtained, medical 
records were studied, and a full clinical examination was 
performed.
Three questionnaires were filled in by parents or legal rep-
resentatives. The first questionnaire was used to collect data 
about pregnancy, first clinical signs and symptoms, mental 
and motor milestones, behavioral problems, sleeping prob-
lems, epilepsy, hearing and vision, digestion, and medical 
history.
To further assess behavior and sleep another two ques-
tionnaires were used: the Aberrant Behavior Checklist (ABC) 
and Sleep Disturbance Scale for Children (SDSC) (Bruni 
et al., 1996; Marshburn & Aman, 1992). In addition, parents 
and/or caregivers were interviewed by Vineland Adaptive 
Behavior Scales (VABS) by one of the researchers. The 
VABS is a widely used instrument, which gives an indication 
of the developmental age (Sparrow & Cicchetti, 1985). The 
reliability of the Vineland in children and adolescents with 
mental retardation proved to be good and the construct valid-
ity is high (Aman, Singh, Stewart, & Field, 1985).
2.4 | Molecular analyses
Before inclusion in this study, patients had been studied at the 
Genome diagnostics laboratory of Radboudumc, Nijmegen, 
The Netherlands. In one individual (IV.4), at the age of 
12  years, some features of AS were recognized, since he 
showed frequent laughter and clumsy movement, although 
not ataxia. The pattern of inheritance, in combination with 
the intellectual disability let to further suspicion of AS in 
these individuals. A deletion and paternal disomy at 15q11-
13 were excluded, but linkage analysis using the following 
fluorochrome markers from proximal 15q11–q13: D15S128, 
D15S1234, D15S1002, and D15S1007, indeed assigned the 
causative genetic defect to 15q11-13 (for comparable anal-
ysis in another family see Meijers-Heijboer et al., 1992). 
Eventually the genetic defect underlying the AS was found 
in one of the individuals in 2002. In 2016 Individuals IV.3 
and IV.4 (see Figure 1) applied for participation in the Dutch 
natural course study and their mother informed us of other 
probands and approached her family members to participate. 
All alive probands in this family were included and after in-
clusion in the study further genetic analysis was performed 
at the Erasmus MC, Rotterdam, The Netherlands. Genomic 
DNA was isolated from peripheral blood using standard 
procedures (Chemagen). Bidirectional sequencing of part 
of exon 7 of UBE3A was undertaken using forward primer 
(5′ TTGCAAAGCGATGAGCAAGCTACC 3′) and reverse 
primer (5′ TGGTCACGTCTAACTTTGAGTCTC 3′). PCR 
conditions are available upon request. Subsequently, the 
PCR products were purified and sequenced using BigDye 
Terminator chemistry v3.1 on an ABI Prism 3130xl ge-
netic analyzer (Applied Biosystems). Sequences obtained 
were analyzed using Sequence Pilot software (JSI Medical 
Systems GmbH). The variant was annotation according to the 
Mutation Nomenclature guidelines from the Human Genome 
Variation Society (HGVS), using reference sequence RefSeq 
NM_130838.4. In silico splice site prediction was per-
formed using Alamut software (Alamut Visual interactive 
biosoftware).
2.5 | Molecular biology
The construction of plasmids expressing mouse 
UBE3A isoform 3 (homologous to human UBE3A iso-
form 1) has been described previously (Avagliano 
Trezza et al., 2019). The p.Asn340del (p.Asn337del 
in mouse UBE3A) mutation was introduced in the 
wild-type UBE3A gene by site-directed mutagen-
esis (Forward: 5′ GAATTTAATAGCCGAAATCT 
AGTGGATGATGATGCCATTGTTG; Reverse: 5′ CAAC 
A A T G G C A T C A T C A T C C A C T A G A T T T C G 
GCTATTAAATTC). For the stability assay a plasmid 
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with an IRES2 (Internal Ribosomal Entry Site) element 
was constructed. First, the IRES2 fragment was amplified 
by PCR using pCAG-CRE-IRES2-GFP (Addgene) as a 
template in order to introduce a 5′ BamHI site and 3′ AgeI 
site. The resulting BamHI-AgeI fragment was inserted into 
pYE581. The multiple cloning site of the first open reading 
frame was replaced using a double-stranded oligonucleo-
tide introducing an HA (hemagglutinin)-tag followed by 
the restriction sites AscI, PmeI, and NotI. mUBE3A-Iso3 
(wild type and variants) was inserted AscI-NotI into the 
first open reading frame. The second open reading frame 
contains HA-GFP which was obtained by amplification of 
pEGFP-N3 (Clontech) in order to introduce a 5′ AgeI site 
followed by a HA-tag, and a 3′ BsrGI site. The resulting 
AgeI-HA-GFP-BsrGI fragment was used to replace the 
tdTomato in pYE581 using the AgeI site in the MCS and 
the internal BsrGI site of tdTomato. For bacterial ubiqui-
tination experiments UBE3A constructs were cloned in 
a pRSF-Duet (Novagen)-derived vector. These UBE3A 
constructs harbor an HA epitope tag at their N-termini. 
Tagging at the N-terminus of UBE3A does not affect its 
ubiquitin ligase activity (Kühnle, Mothes, Matentzoglu, 
& Scheffner, 2013). The UBE3A target Ring1b-I53S (a 
catalytically inactive mutant of Ring1b, generous gift of 
Martin Scheffner) was cloned in pMB419, a derivative of 
pCOLA-Duet1 (Novagen). Details on the construction of 
the plasmids and validation of the bacterial ubiquitination 
system will be described elsewhere (R. Avagliano Trezza 
et al., manuscript in preparation).
2.6 | Bacterial ubiquitination assay
The bacterial ubiquitination assay can be used to recapitu-
late the mammalian ubiquitination cascade in E. coli cells 
(Keren-Kaplan et al., 2011). BL21-GOLD (DE3) cells were 
co-transformed with bacterial expression constructs encod-
ing E1, UbcH5c, ubiquitin, as well as UBE3A variants, and 
the substrate RING1b-I53S. Transformants were selected 
on solid LB medium (1% (w/v) Bacto tryptone, 0.5% (w/v) 
Bacto yeast extract, 1% (w/v) NaCl, and 1.5% agar) with an-
tibiotics as required and single colonies were inoculated in 
overnight culture of LB medium supplemented with 2% glu-
cose and 50 mM Tris/HCl (pH 8.0). The following morning 
cells were inoculated at a starting OD600 of 0.2 and grown 
to OD600 0.7 at 21°C. Upon reaching requisite OD600, pro-
tein expression was induced by addition of 0.5 mM isopropyl 
B-D-1-thiogalactopyranoside (IPTG) and growth was con-
tinued at 16°C for 16–18 hrs. The following day, cells were 
lysed in 0.5 ml lysis buffer (50 mM sodium-phosphate pH 
8.0, 300 mM NaCl, 5% glycerol, 5 mM 2-mercaptoethanol, 
1 mM PMSF, RNase [0.01 mg/ml], DNase [0.01 mg/ml], and 
protease inhibitor cocktail) by sonication. Cellular debris was 
removed by centrifugation (30 min, 13,000× g) and cleared 
protein lysate was used for SDS-PAGE and western blotting.
2.7 | Stability in HEK293T cells
Protein stability of UBE3A variants was analyzed in HEK293T 
cells by transient transfection of mammalian expression con-
structs (2 μg DNA per sample) encoding UBE3A variants. 
Forty-eight hours post-transfection cells were harvested. Cell 
pellets were taken up in 1X Laemmli sample buffer (0.2 M 
Tris–HCl [pH 6.8], 1.5% sodium dodecyl sulfate [SDS], 10% 
glycerol, 1 mM EDTA, 0.004% bromophenol blue) contain-
ing protease inhibitor cocktail and cells were lysed by sonica-
tion (3 × 4 s, 5 mAmp). Protein lysate (10 μg) was analyzed 
by SDS-PAGE and western blotting.
2.8 | Cycloheximide chase
Protein stability of UBE3A variants was analyzed using a cy-
cloheximide chase assay in HEK293T cells. HEK293T cells 
were transiently transfected with mammalian expression 
constructs (2 μg DNA per sample) encoding UBE3A vari-
ants. Twenty-four hours post-transfection cells were treated 
with cycloheximide [70 μg/ml) and chased across different 
time periods. At the conclusion of each time period cells 
were harvested in ice-cold PBS (Sigma) and briefly cen-
trifugated (5  min, 1600× g). Cell pellets were taken up in 
1X Laemmli sample buffer (0.2 M Tris–HCl [pH 6.8], 1.5% 
sodium dodecyl sulfate [SDS], 10% glycerol, 1 mM EDTA, 
and 0.004% bromophenol blue) containing protease inhibi-
tor cocktail and cells were lysed by sonication (3 × 4 s, 5 
mAmp). Protein lysate (15 μg) was analyzed by SDS-PAGE 
and western blotting.
2.9 | Western blot analysis
For western blot analysis, approximately 20 μg of total pro-
tein lysate per sample was separated by SDS-PAGE and 
transferred onto nitrocellulose membranes. Next, mem-
branes were blocked in TBS (10  mM Tris–HCl (pH 8.0), 
150 mM NaCl) containing 5% (w/v) powdered milk for 1 hr 
at room temperature, washed three times in TBS-T (TBS with 
0.1% Tween-20, Sigma P1379) and incubated at 4 °C over-
night, rotating end-over-end, with the primary antibody dis-
solved in TBS-T with 2% (w/v) milk solution. The day after, 
membranes were washed three times for 10 min with TBS-T 
and incubated with the secondary antibody dissolved in TBS-T 
with 2% (w/v) milk for 1 hr. At the end of the incubation, 
membranes were washed three times for 10 min with TBS and 
analyzed by measuring enhanced chemiluminescence (ECL). 
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Antibodies used for western blotting were: Mouse monoclo-
nal anti-UBE3A (Sigma SAB1404508), Mouse monoclonal 
anti-V5 horseradish peroxidase (HRP)-conjugated (Thermo 
Fisher Scientific R961-25), Rat monoclonal anti-HA HRP-
conjugated (Roche 12013819001), Mouse monoclonal anti-
UBE3A (Sigma E8655), and Mouse monoclonal anti-GFP 
(Roche 11814460001).
3 |  RESULTS
The pedigree of the family with the novel UBE3A variant 
is shown in Figure 1a, with images of all living patients in 
Figure 1b. Main clinical information is provided in Table 1, 
together with an overview of level of functioning regarding 
communication, activities of daily living and social and 
motor skills as given by the VABS in Table 2. Overall, 
the phenotype in probands in this family did not meet the 
clinical criteria of AS described in the Updated Consensus 
for Diagnostic Criteria of AS 2005 (Williams et al., 2006). 
Probands showed a milder degree of intellectual disability 
and were able to speak a few words or small sentences with 
the exception of individual III.2 who was not able to speak 
(Table 1). Affected individuals could walk long distances 
with only mild or no ataxia (Ind. III.3 and III.5). None of 
the affected individuals showed scoliosis or microcephaly. 
No hearing or visual deficits were observed except for 
individual IV.3 who showed mildly impaired vision and 
hearing. Facial features typical for AS such as protruding 
tongue, wide mouth, and widespread teeth were absent in 
T A B L E  1  Clinical features present in the probands
III.2 III.3 III.4 III.5 III.10 III.11 IV.3 IV.4
Sex M M F F M F M M
Birth weight 
(grams)
NA NA NA NA NA NA 3140 3220
Perinatal problems NA NA NA NA − NA − −
Age of walk (years) NA NA NA NA NA NA 3 3
Ataxia of gait − ± − ± − − − −
Tremors − ± − + − − − ±
Frequent laughter − − − − − − +
Hyperactive 
behavior
+ − − − − − − −
Attention deficit + − − − − − − −
Hand flapping − − − − − − − −
Development delay + + + + + + + +
Speech Absent Sentences Words Words Sentences Sentences Sentences Sentences
Microcephaly NA − NA − − − − −
Seizures − − − + − + − −
Hypotonia − − − − − − − −
Feeding problems − − − +a − +b +c +d 
Flat occiput NA − NA − − − − +
Hypopigmented 
skin
NA − NA − − − − −
Strabismus NA − NA − − − + −
Wide mouth NA − NA − − − − −
Wide-spaded teeth NA − NA − − − − −
Protruding tongue Na − NA − − − − −
Scoliosis − − − − − − − −
Note: Clinical features as defined by Williams et al. (2006).
Abbreviations: NA, not available; −, absent; ±, mild; +, present.
aSwallowing problems. 
bHistory of obesity. 
cObesity. 
dFeeding problems as an infant, reflux. 
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the probands. Other clinical symptoms such a characteristic 
behavioral symptoms, epilepsy, and sleep disturbance were 
absent in most of the affected individuals. Hyperactive be-
havior and attention deficit was only observed in individual 
III.2 (male, †66  years). Probands III.3, III.10, IV.3, and 
IV.4 were socially outgoing and happy, enjoying the visits 
of the researchers, while III.11 was a bit reluctant. Since 
individuals with a comparable intellectual disability are 
frequently socially outgoing as well, the researchers find it 
difficult to indicate if this behavior is consistent with AS or 
appropriate for their developmental age. Sleep disturbance 
and epilepsy was seen in individuals III.5 and III. 11. Ind. 
III.5 (female, 57 years) had sleeping problems her whole 
life and got her first epileptic seizure at the age of 16. The 
total amount of epileptic seizures in her life is 10. For in-
dividual III. 11 (female, 43  years) no sleeping problems 
were reported, but she had 2–4 epileptic seizures during 
her life. Feeding problems, another typical phenotype of 
AS patients, were present in only four of the eight affected 
individuals (III.5, III.11, IV.3, and IV.4). Two affected in-
dividuals were found to have obesity due to a lack of sati-
ety (III.11 and IV.3).
Sequencing analyses of UBE3A revealed the sequence 
variant NM_130838.4(UBE3A):c.1018-1020del, p.(Asn-
340del) on the maternally inherited allele in III.3, III.5, 
III.10, III.11, IV.3, and IV.4. Sequence analyses in III.6 
revealed no nucleotide changes in UBE3A. In III.1 p.(Asn-
340del) was detected on the paternally inherited UBE3A 
copy. The variant leads to an in-frame deletion in a non-re-
petitive region. There was no predicted effect on splic-
ing (Splice Site Finder Like, MaxEntScan, NNSPLICE, 
GeneSplicer). The sequence variant was not present in the 
public database gnomAD (V2.1).
Previous reports have shown that AS-linked variants in 
UBE3A may affect the function of UBE3A by changing its 
subcellular localization, E3 ubiquitin ligase activity, or sta-
bility (Avagliano Trezza et al., 2019; Cooper et al., 2004; 
Yi et al., 2015). The p.Asn340del variant is located in the 
N-terminal half of UBE3A well outside the catalytic HECT 
domain (Figure 2a). To determine if the p.Asn340del vari-
ant affects UBE3A localization we deleted the Asn resi-
due of mouse UBE3A at position of 337, which is the 
homologous position in mouse UBE3A isoform 3, fused at 
its C-terminus to GFP (mUBE3A-iso3N337Δ-GFP). Mouse 
primary neurons transfected with mUBE3A-iso3N337Δ-GFP 
showed a predominant nuclear localization that was indis-
tinguishable from that of wild-type mUBE3A-iso3-GFP, 
indicating that the p.Asn340Δ variant does not affect the 
localization of UBE3A (Figure 2b).To assess E3 ubiqui-
tin ligase activity, we modified a previously established 
bacterial ubiquitination system where the mammalian 
ubiquitination cascade can be recapitulated by co-trans-
forming bacterial expression constructs containing the req-
uisite enzymes (Avagliano Trezza & Distel, unpublished 
data). We first tested the ability of mUBE3A-iso3N337Δ 
to ubiquitinate itself, an activity also known as auto- of 
self-ubiquitination (Nuber, Schwarz, & Scheffner, 1998). 
In the absence of a target, the mUBE3A-iso3N337Δ variant 
showed auto-ubiquitination levels comparable to wild-type 
mUBE3A (Figures 2c,e and S1). In the presence of target 
RING1bI53S (a catalytic inactive variant unable to ubiquiti-
nate itself) both wild-type mUBE3A and the mUBE3A-
iso3N337Δ variant show comparable levels of RING1B 
ubiquitination (Figures 2d,f and S1).
To determine if the mUBE3A-iso3N337Δ variant af-
fects protein levels in vivo we introduced the mutation in 
mUBE3A-iso3 and transfected the expression construct into 
HEK293T cells. Protein levels of the mUBE3A-iso3N337Δ 
variant were compared to wild-type mUBE3A-iso3 and 
mUBE3A-iso3C21Y, a variant that causes AS and has been 
previously shown to be unstable (Cooper et al., 2004; Yi et al., 
2015). Quantification of the western blots revealed similar 
protein levels of mUBE3A-iso3N337Δ compared to wild-type 
mUBE3A-iso3 (p = 0.1331), whereas the mUBE3A-iso3C21Y 
variant was detected at significantly lower levels (p = 0.0011) 
(Figures 2g and S2). Next, we determined the protein stabil-
ity of these UBE3A variants in a cycloheximide chase exper-
iment (Figure 2h). This experiment showed that the stability 
of mUBE3A-iso3N337Δ, within the analyzed timespan, is sim-
ilar to that of wild-type mUBE3A, whereas the mUBE3A-is-
o3C21Y variant is already present at much lower levels and 
disappears within 8 hrs. Together these data show that nu-
clear localization, ubiquitin ligase activity, and stability of 
the mUBE3A-iso3N337Δ protein are not significantly affected.
III.3 III.5 III.10 III.11 IV.3 IV.4
Communication 23a 14 22 33 27 22
Activities of daily 
living
35 22 76 70 46 44
Social skills 21 8 33 39 42 57
Motor skills 36 16 56 56 34 41
aDevelopmental age in months per category. 
T A B L E  2  Vineland results
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4 |  CONCLUSION
We identified a shared, maternally inherited, Ube3A se-
quence variant (p.Asn340del) in eight related individuals 
with a clinical phenotype that does not match the consensus 
clinical criteria of AS (Williams et al., 1995, 2006). Although 
all probands showed an apparent intellectual disability rang-
ing from severe to moderate, they showed a milder degree of 
intellectual disability, were less affected in speech and did 
not show the ataxia typically seen in individuals with AS. 
While some notable clinical variation is present in the af-
fected members of this family, the phenotypic differences 
between the probands carrying the p.Asn340del sequence 
variant and individuals with AS due to other genetic causes 
of AS is however substantial, and clinical criteria are not 
met. In our opinion it is, therefore, not appropriate to clas-
sify these patients as “mild, attenuate or atypical Angelman” 
or “Angelman-like.” Patients with a nonclassical AS pheno-
type have been described in some patients with an imprinting 
defect (Burger, Kunze, Sperling, & Reis, 1996; Fairbrother 
et al., 2015; Gillessen-Kaesbach et al., 1999) as well as 
in AS patients with paternal uniparental disomy (Bottani 
et al., 1994; Brockmann, Böhm, & Burger, 2002; Fridman, 
Varela, Nicholls, & Koiffmann, 1998; Gillessen-Kaesbach, 
Albrecht, Passarge, & Horsthemke, 1995). More recently a 
milder phenotype was reported for three individuals that have 
a mutation in the start codon of human UBE3A isoform 1 
(p.Met1Thr), which is predicted to result in loss of expres-
sion of isoform 1, but not of isoforms 2 and 3. (Sadhwani 
et al., 2018). Similar to the affected individuals described in 
this report, the majority of our patients had normal gait and 
used language spontaneously to express their needs, exceed-
ing developmental skills seen in other individuals with AS. 
This was also confirmed by the relatively high scores on the 
Vineland Adaptive Behavior Scales. On a molecular level, 
individuals with the p.Met1Thr variant lack the most abun-
dantly expressed human isoform 1, which is homologous 
to the nuclear mouse isoform 3 (Avagliano Trezza, 2019). 
However, they do express the less abundant isoforms 2 and 
3, resulting in low levels of ligase competent UBE3A, which 
may explain their relatively mild phenotype.
Results from analyses with polymorphic markers provided 
supporting evidence of p.(Asn340del) being the causative 
variant in this family. The sequence variant p.Asn340del was 
identified on the maternally inherited UBE3A allele in all af-
fected individuals and was not detected in III.6. Moreover, 
the unaffected mother (III.1) of two affected brothers, IV.3, 
and IV.4, was found to carry the p.Asn340del sequence vari-
ant on her paternally inherited Ube3A allele, confirming the 
dependency on imprinting.
The p.Asn340del mutation is located in a mutational 
hotspot in the N-terminal half of UBE3A. Recent evidence 
suggests that the UBE3A N-terminal domain (where the 
p.Asn340del variant is located) interacts with the HECT 
domain and that these intramolecular interactions can mod-
ulate the catalytic activity of UBE3A (Mortensen et al., 
2015; Sailer et al., 2018). It is conceivable, therefore, that 
mutations in the N-terminal domain can impact the func-
tion of UBE3A. In line with this, previous work of Yi and 
colleagues has shown that AS-linked missense mutations 
in this specific region of the UBE3A N-terminal domain 
can result either in decreased, intrinsic, protein stability, 
or reduced HHR23A (target) ubiquitination (Yi et al., 
2015). Functional analyses of the p.Asn340del (mouse 
p.Asn337Δ) variant indicated that nuclear localization and 
ubiquitin protein ligase activity (both auto-ubiquitination 
and target, Ring1b, ubiquitination) of mUBE3A-iso3N337∆ 
were unaffected in our in vitro/in vivo assays (Figure 2c-f). 
Protein levels of mUBE3A-iso3N337∆ were comparable to 
mUBE3A-iso3 when expressed in HEK293T cells (Figure 
2g) and we did not observe a difference in intrinsic pro-
tein stability in a cycloheximide chase experiment (Figure 
2h). While this data indicate that the p.Asn340del (mouse 
p.Asn337Δ) variant does not have major functional defi-
cits, subtle changes in activity or localization may not be 
detected in our vitro/in vivo assays. Also, we have tested 
F I G U R E  2  Functional analysis of the mUBE3A-p.Asn337del variant (homologous to hUBE3A-p.Asn340del). (a) Schematic representation 
of human UBE3A isoform 1 with functional domains, N-terminal Zn-binding domain (AZUL) and C-terminal HECT (homologous to E6AP 
C-terminus) domain, and location of the p.Asn340del mutation. (b) Localization of mUBE3A-Iso3 and the p.Asn337del variant in neurons. 
E16.5-derived hippocampal neurons transfected at 4 days in vitro (DIV4) with the indicated mUBE3A-Iso3 variants C-terminally tagged with 
GFP, were fixed and stained at DIV8. UBE3A-GFP expression was detected by direct fluorescence (green, top panels) together with MAP2 (pink, 
lower panels). E. coli cells expressing E1, UbcH5 (E2) and with or without ubiquitin were transfected with a plasmid expressing mouse HA-
tagged mUBE3A (wild-type, catalytically inactive [C817S] or Asn337del) (c) or with the same HA-mUBE3A variants and V5-RING1B-I53S, a 
catalytically inactive RING1B variant that is unable to ubiquitinate itself (d). Cell lysates were analyzed by SDS-PAGE and immunoblotting using 
HA antibody to visualize UBE3A (c) and V5 antibody to visualize RING1B (d). (e, f) Quantification of catalytic activity. Values are shown as 
mean percentage ± SD of WT UBE3A activity (set at 100%). N = 3, *p < 0.05, **p < 0.01. (g) Quantification of expression levels of mUBE3A 
constructs. HEK293T cells were transiently transfected with mUBE3A, mUBE3AN337Δ or mUBE3AC21Y and protein levels were determined by 
anti-UBE3A western blotting. All data represent mean ± SD and are normalized against actin. Wild-type (WT) UBE3A levels were set to 100%. 
N = 3, **p < 0.05. (h) Protein stability of mUBE3A variants. HEK293T cells transfected with the indicated mUBE3A expressing plasmids and a 
plasmid expressing GFP (transfection control). Twenty-four hours post-transfection, cells were treated with cycloheximide (70 μg/ml) and chased 
across different time periods. Blots were probed with anti-HA and anti-GFP antibodies
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the ubiquitination of a single target, Ring1b, whose ubiq-
uitination by the p.Asn340del variant is unaffected, but if 
ubiquitination of other UBE3A targets is changed remains 
to be investigated. Despite these limitations, our data indi-
cate that the functional changes caused by the p.Asn340del 
variant must be subtle, a conclusion that is supported by the 
relatively mild phenotypes observed in the affected individ-
uals. Further studies are required to clarify how the UBE3A 
p.Asn340del variant differs from wild-type UBE3A as well 
as from variants that cause typical AS phenotypes. Such 
studies may provide more insight into the biochemical 
function of UBE3A and its role in neurodevelopment.
With the rapidly increasing use of whole-exome se-
quencing (WES) we expect variants with uncertain mean-
ing due to discrepancy of the phenotype of the patients as 
opposed to the phenotype known to be associated with mu-
tations in the gene, to expand (Tetreault, Bareke, Nadaf, 
Alirezaie, & Majewski, 2015). It is, therefore, important to 
collaborate internationally on the gathering of genotypes 
and phenotypes. Furthermore, our current work empha-
sizes that such studies should be accompanied with func-
tional studies of the mutant protein to further understand 
and delineate the range in clinical phenotype caused by dif-
ferent mutations in UBE3A.
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